Research Paper Volume 15, Issue 24 pp 14996—15024
ATRX is a predictive marker for endocrinotherapy and chemotherapy resistance in HER2-/HR+ breast cancer through the regulation of the AR, GLI3 and GATA2 transcriptional network
Figure 5. Immune analyses for GSE22513. (A) CIBERSORT analysis for 22 immunity cells. (B) ssGSEA revealed the difference in the 22 immunity cells between the ATRX-High and ATRX-Low groups. (C) Relationship between the five genes and immunity cells.